Hood River Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Hood River Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-238,670	Closed	-$34.8M	–	146
2022 Q2	$34.8M	Buy	238,670 +7,133	+3%	+$911K	1.38%	22
2022 Q1	$27.5M	Sell	231,537 -68,435	-23%	-$8.54M	0.91%	41
2021 Q4	$41.3M	Buy	299,972 +214,452	+251%	+$27.3M	1.24%	27
2021 Q3	$11.9M	Sell	85,520 -231,828	-73%	-$28.9M	0.37%	75
2021 Q2	$30.8M	Sell	317,348 -4,739	-1%	-$385K	0.92%	41
2021 Q1	$22M	Buy	322,087 +113,141	+54%	+$9.15M	0.71%	57
2020 Q4	$17.9M	Buy	208,946 +3,326	+2%	+$282K	0.59%	70
2020 Q3	$13.4M	Sell	205,620 -20,662	-9%	-$1.35M	0.58%	69
2020 Q2	$16.5M	Buy	+226,282	New	+$12M	0.74%	51

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hood River Capital Management's BHVN Position: Q3 2022 in Review

Hood River Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 238,670 shares — an estimated $34.8M sold.

Hood River Capital Management first reported a position in BHVN in Q2 2020 and held it in 9 quarters. The position peaked at $41.3M in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Hood River Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Hood River Capital Management sold 238,670 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $34.8M.
Hood River Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 9 quarters.
Hood River Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $41.3M in Q4 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Hood River Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.